Objective: Prior analysis in the Open vs Endovascular Repair Veterans Affairs (VA) Cooperative Study (CSP #498) demonstrated that survival, quality of life, and total health care costs are not significantly different between the open and endovascular methods of repair of abdominal aortic aneurysm. The device is a major cost of this method of repair, and the objective of this study was to evaluate the costs of the device, abdominal aortic aneurysm repair, and total health care costs when different endograft systems are selected for the endovascular repair (EVR . Mean device, hospitalization, and total health care costs from randomization to 2 years were compared. Health care utilization data were obtained from patients and national VA and Medicare data sources. VA costs were determined using methods previously developed by the VA Health Economics Resource Center. Non-VA costs were obtained from Medicare claims data and billing data from the patient's health care providers. Results: Implant costs were 38% of initial hospitalization costs. Mean device (range, $13,600-$14,400), initial hospitalization (range, $34,800-$38,900), and total health care costs at 2 years in the endovascular (range, $72,400-$78,200) and open repair groups (range, $75,600-$82,100) were not significantly different among device systems. Differences between endovascular and corresponding open repair cohorts showed lower mean costs for EVR (range, $3200-$8300), but these were not statistically different. Conclusions: The implant costs of endovascular aneurysm repair are substantial. When evaluating total health care system expenditures, there is large individual variability in costs, and there is no significant difference at 2 years among systems or when an individual system is compared with open repair. (J Vasc Surg 2015;61:59-65.) Efforts to contain health care costs have gained greater prominence, and physicians are in a pivotal role of determining which treatments their patients receive. Endovascular repair (EVR) of abdominal aortic aneurysms (AAAs) is particularly visible, with high volume and very high device cost. Victor Fuchs has stated, The role of new medical technology deserves special attention in thinking about future health care spending because biomedical innovations as a whole have been the primary source of both improvements in health and increasing expenditures. On the one hand, it is fiscally irresponsible to continue to accept innovations regardless of cost, even if they pass tests of safety and efficacydand it is particularly irresponsible when the interventions are provided at public expense. On the other hand, we must avoid an innovation policy that cuts off new interventions prematurely. 2-4 Comparisons of costs have been evaluated with contrasting results, with some studies showing cost-effectiveness of EVR, and others finding EVR was more costly. 2, [5] [6] [7] 
Efforts to contain health care costs have gained greater prominence, and physicians are in a pivotal role of determining which treatments their patients receive. Endovascular repair (EVR) of abdominal aortic aneurysms (AAAs) is particularly visible, with high volume and very high device cost. Victor Fuchs has stated, The role of new medical technology deserves special attention in thinking about future health care spending because biomedical innovations as a whole have been the primary source of both improvements in health and increasing expenditures. On the one hand, it is fiscally irresponsible to continue to accept innovations regardless of cost, even if they pass tests of safety and efficacydand it is particularly irresponsible when the interventions are provided at public expense. On the other hand, we must avoid an innovation policy that cuts off new interventions prematurely. 1 Several randomized trials have demonstrated similar long-term survival and quality of life when AAAs are electively repaired by EVR or open methods. [2] [3] [4] Comparisons of costs have been evaluated with contrasting results, with some studies showing cost-effectiveness of EVR, and others finding EVR was more costly. 2, [5] [6] [7] The Department of Veterans Affairs (VA) Open vs Endovascular Repair (OVER) trial (ClinicalTrials.gov number, NCT00094575) reported a comparison of costs at 2 years between EVR and open repair of AAA. Specifically, mean graft costs were higher with EVR ($14,052 vs $1363; P <.001), but length of stay was shorter (5.0 vs 10.5 days; P <.001), with the result that the mean AAA repair hospitalization cost is less with EVR (difference, $5901; 95% confidence interval [CI] , $821-$12,135). Further, total health care costs were not significantly lower with EVR (difference, $5019; 95% CI, À$4928 to $16,720). 5 We studied device, hospitalization, and total health care costs when different devices are used for EVR to inform physicians on the cost implications of device selection.
METHODS
The general methods, clinical outcomes, and costeffectiveness of the OVER trial have been reported previously in detail. 4, 5 The study was approved by a central human rights committee and the Institutional Review Boards at each participating center. Informed consent was obtained from all participants. Between October 2002 and April 2008, 881 patients were randomized at 42 VA medical centers: 444 to EVR and 437 to open repair. There was no statistically significant difference between the groups in major morbidity, reintervention, aneurysm-related hospitalization, or health-related quality of life.
The device system was selected and documented by the local investigator before randomization, and so open control patients correspond with each device cohort. Data were excluded for two low-volume devices that were implanted in only 13 patients. The clinical trial database of OVER patients was linked to national VA and Medicare databases to obtain information on health care utilization and cost. The device components used for each patient were recorded in the OVER case report forms, and prices were obtained from the VA's National Patient Prosthetics Database. This did not include backup devices that were not implanted.
Hospitalization costs of AAA repair were obtained from the VA Decision Support System (DSS) National Data Extracts. 8 The DSS combines data from accounting, payroll, patient care, and administrative sources to calculate costs, which can be categorized in six mutually exclusive categories: surgery, nursing, laboratory, radiology, pharmacy, and others. Each of these includes fixed direct costs that are related to the direct provision of care and do not vary by volume, such as clerical personnel and nursing supervisor time, and fixed indirect costs that are indirectly related to care and do not vary by volume, such as building maintenance, housekeeping, engineering, and administration. These costs are assigned per diem according to individual length of stay.
Local VA electronic medical records were used to identify VA utilization data, including other hospital stays, outpatient visits, contract care, and outpatient medications acquired from VA. These data were obtained from the VA Medical SAS Inpatient and Outpatient Datasets extracted from the National Patient Care Database, which captures information from local electronic medical records. 9, 10 Fee basis files captured care provided to VA patients by contract providers outside of VA facilities.
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Nonrepair hospitalization costs were obtained from the VA Health Economics Resource Center (HERC) average cost data sets, [12] [13] [14] which are modeled from Medicare claims data and adjusted to costs using cost-to-charge ratios from reports to the Center for Medicare and Medicaid Services. 12 Costs for nonacute hospital stays (eg, rehabilitation, mental health, and long-term care) were calculated from length of stay and average daily cost from the DSS National Data Extracts. Costs for VA outpatient visits were based on reimbursement rates of Medicare and other payers. Prescriptions costs were based on the VA's acquisition and dispensing costs from the VA DSS National Data Extracts Pharmacy Datasets. 15 Non-VA health care utilization was obtained from Medicare claims data and from patient reports verified with billing data from the facilities where care was received. Costs were estimated by multiplying the Medicare charges by the hospital-specific cost-to-charge ratios. 16 Total health care costs were summed from all of the above; that is, the VA and private-sector providers. Costs were adjusted to 2008 United States dollars with the Consumer Price Index. À3900 (À27,800 to 11,400) À8300 (À27,100 to 6000)
We compared costs among different devices and between patients randomized to endovascular and open repair on an intention-to-treat basis, regardless of the occurrence or type of the actual AAA repair. Total health care costs include initial repair, nonacute care hospitalization, nonrepair hospitalization, surveillance imaging, reinterventions, outpatient care, prescriptions, and non-VA hospitalization costs. Mean, median, and interquartile values are provided and are rounded to the nearest $100. Calculation of 95% CIs used bias-corrected accelerated bootstrapping procedures without assumption about the data having a normal distribution. A sensitivity analysis was conducted to evaluate for censoring because of differences in 2-year mortality rates by using Kaplan-Meier sample average estimators.
RESULTS
The mean cost (61 standard deviation) of the device, initial hospital admission, and total health care costs at 2 years are presented in Table I . The device was 38% of Zenith ÀAneuRx Excluder ÀAneuRx 88 9 14,300 (4200) 800 (100-1400) 100 (À800 to 1100) À700 (À1800 to 300) 38,900 (24,900) 3300 (À3400 to 8800) À800 (À8100 to 5400) À4100 (À11,300 to 2800) 4800 (À9600 to 17, 100) 5800 (À6900 to 18,800) 1000 (À11,500 to 14,000) 72,400 (42,400) 61,900 (43,900, 82,500) 98 6 300 (À18,800 to 24,800) 6500 (À17,500 to 30,600) 6200 (À17,800 to 25,300) 75,600 (84,100) 52,100 (34,700, 76,100) À3200 (À27,200 to 11,600) Table I . Continued. the initial costs of hospitalization. There is relatively greater variability in hospitalization and total health care costs than the device costs. The source of variability is typical of health care cost data often due to prolonged inpatient admissions. When selected EVR device systems were compared, no statistically significant difference was found in device, hospitalization, or total health care costs at 2 years. There was no statistically significant difference between EVR and open repair when a specific device system was selected, although mean total health care costs were lower in each cohort, ranging from $3153 to $8333. Specific cost breakdowns are provided in Tables II-V . The sensitivity analysis showed survival adjusted costs were similar (Table VI) .
CONCLUSIONS
Physicians are increasingly integrated with hospitals, and reimbursement models are being piloted with bundled payments and shared savings. Data abound on clinical outcomes with different EVR systems, but cost data to inform selection of devices are scant. In this multicenter randomized trial, total health care costs after 2 years after repair were not significantly different between EVR and open repair of AAA in the group as a whole and when analyzed by the specific device selected for EVR. Shorter hospital and intensive care stays result in lower hospital costs with EVR compared with open repair, despite the high cost of the endovascular grafts, which account for almost two-fifths of the hospitalization cost. Devices are a substantial portion of hospitalization costs; however, there are also improvements in the model of care of AAA patients that may reduce costs in the $60,000 to $70,000 of total health care costs not spent on the device, and these also represent large targets of opportunity.
Mean hospitalization costs have been presented, which informs decision making in a classic volume-based reimbursement system, such as a hospital diagnosis-related group. 17 Total health care costs have also been presented, which helps guide decision making in a population health environment, such as an all-risk capitated system and a shared savings Accountable Care Organization. Device selection does not have a statistically significant effect on downstream costs in the system for the next 2 years. This suggests that other factors, such as longer-term clinical outcomes and price should inform device selection. 18, 19 Limitations of this analysis have been discussed previously. 5, 17 The cost-accounting does not have granularity and may miss some items: prerandomization evaluation; equipment or supplies that are included in direct fixed costs but are only applicable to one treatment cohort, such as an autologous blood salvage setup or a deployment handle for a specific device; and backup device inventory that is not implanted. There are some potential distortions related to protocol-required testing that may not be part of current clinical routines. These data are derived from 42 VA medical centers and may not directly apply to other populations in other health care systems. However, the VA is a large integrated health care system in the United States, providing care to >6 million veterans 20 to whom these results are 9900 (6700-20,100) 8700 (5500-16,700) 9300 (5400-13,400) Total at 1 year 61,400 (48,800) 59,100 (52,700) 57,900 (32,000) Median (IQR) 49,600 (40,100-64,900) 43,800 (34,100-62,800) 49,000 (39,000-64,800) AAA repair, 1 year to 2 year 0 (0) 0 (0) 0 (0) 1 year to 2 years, other VA costs Acute inpatient care 6100 (19,800) 3400 (13,700) 1400 (4300) Rehabilitation, mental health, and long-term care 300 (4000) 700 (9400) 0 (0) Outpatient visits 4800 (4600) 6100 (10,000) 6600 (11,400) Outpatient pharmacy 1200 (1700) 1100 (2100) 1200 (1300) Non-VA Costs Acute inpatient care 2500 (12, 500) 1700 (6200) directly applicable, and these accounting methods are commonly used in federally funded economic studies. Finally, the VA has a central procurement process and may have lower costs than non-VA users, and these findings may not apply in systems in which endovascular grafts costs are substantially different from those in the OVER trial. However, we have presented the data in a manner that allows other systems to factor in their specific device costs.
Endovascular aneurysm repair implant costs are substantial. When evaluating total health care system expenditures, there is large individual variability in costs, and there is no significant difference at 2 years among systems or when an individual system is compared with open repair. 
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